Life Sciences Archive » January, 2013

Life Sciences - January, 2013

253 articles

• J&J Vaginal Mesh Plaintiff Says She Was Used As Guinea Pig
• Merck & Cie Wins $11.6M Over Acella's Supplements Marketing
• FTC Chief Leibowitz To Exit Agency In February
• P&G Gets Probiotic False Ad Action Pared
• DePuy Exec Called Hip Implant Study 'Suicide,' Jury Hears
• MAP Pharma Investor Sues To Stop Allergan's $958M Buy
• Device Makers Balk At Medicare Bidding Expansion
• Merck Shareholders Win Cert. In Vioxx Stock Fraud MDL
• Pfizer Ducks False Ad Suit Over Immune Supplement
• 2nd Circ. Upholds Merck Win In Bellwether Fosamax Trial
• Purdue Hits 2 Generics Makers With OxyContin Patent Suits
• Stryker Hip Implant Litigation Consolidated In Bergen County
• Ciba Knocks Out O2 Optix Contact Lens Injury Suit
• FCC Approves More Flexible Experimental Device Rules
• EU Says J&J, Novartis Pay-For-Delay Breached Antitrust Laws
• Determining Insurance Coverage In Food-Recall Disputes
• Watson Can't Prove Rapamune Patent Invalid, Judge Says
• JPML To Mull Novel Bankruptcy Shift In Meningitis Cases
• Krill Oil Co. Says Rivals Infringe Patent In ITC Suit
• FDA OKs Isis Orphan Drug Amid Shareholder's Safety Suit
• BMS, Sanofi Can't Shake FCA Suit Over Plavix Marketing
• AMA, AARP Back FTC In Pay-For-Delay Antitrust Fight
• NJ Judge OKs $8.1M Par Securities Settlement For Now
• DePuy CEO Testifies On Aussie Pullout In Hip Implant Suit
• Allergan, Duke Get Generic Lash-Growth Treatments Blocked
• French Watchdog Pulls Bayer Acne Drug Over Clotting Risk
• FDA Official Says Off-Label Ruling Won't Limit Enforcement
• McDermott Slams Suit Over Ex-Atty's Alleged IP Theft
• Discovery In J&J FCA Suit Was Too Narrow, 1st Circ. Hears
• Seeking Insurance Coverage For FDA Inspections Under FSMA
• Skadden Reps JLL Partners Unit In Medical Tech Buys
• Morgan Lewis Picks Up McDermott PE Pro
• Fed. Circ. To Mull Whether USPTO's Patent Term Math Adds Up
• Duane Morris Bolsters IP Group With Locke Lord Veteran
• Zinc Evidence Belongs In P&G Fixodent Case, 11th Circ. Told
• Drug Misbranding Investigations Remain Top Priority: DOJ
• Bristol-Myers, Sanofi Topple Plavix False Marketing Suit
• Lilly Fights Cymbalta 'Brain Zaps' Suit, Saying It Warned Docs
• Cephalon, SciMedica Can't Derail TCPA Class Action
• Generic Medical Foods Not Identical To Pamlab's, Suits Say
• Apotex Strikes Licensing Deal To Settle Pennsaid IP Row
• Pharma Exec Criminal Convictions And HHS Program Bans
• Genetically Modified Food Can Feed The Planet
• Fed. Circ. Upholds Allergan Win Over Lumigan Patent
• DePuy Hip Implant's Failure Rate 'Striking,' Jury Told
• FCA Expansion Fight May Land In High Court
• 3rd Circ. Says Pa. Fen-Phen Suit Barred By Earlier MDL Deal
• Sanofi, Bristol-Myers Defeat Plavix Failure-To-Warn Suit
• Europe To Review Blood Clot Risks In Contraceptives
• Judge Freezes Assets Of Execs Tied To Meningitis Outbreak
• Myriad Can't Patent Cancer Genes, ACLU Tells High Court
• Eye Med Distributor's $100M Suit Barred By Deal, Akorn Says
• Pfizer Sues Wockhardt To Block Lyrica Generic
• And Now A Word From The Panel ...
• Consumers Urge Wider Recall In Ranbaxy Glass Shards Action
• How Already V. Nike Could Impact Hatch-Waxman Cases
• AstraZeneca Escapes Medco FCA Kickbacks Suit
• Health Groups Accuse Device Firms Of Shirking $30B ACA Tax
• FDA OKs Merck's OTC Treatment For Overactive Bladder
• Nexium MDL Judge Scolds Attys For Lead Counsel 'Squabble'
• Sandoz Generics Claims Survive, Despite Post-Mensing Trend
• FDA Panel Votes For Tougher Controls On Hydrocodone
• J&J Unit DePuy Knew Of Hip Implant Defect, Jury Hears
• AbbVie Sues Sun Pharmaceutical Over Generic Zemplar
• McKesson, Sales Reps Reach $1.2M Accord In FLSA Action
• Glenmark Sues GSK To Invalidate Antibiotic Cream Patents
• Banker Accused Of Aiding Olympus' $2B Plot Gets Bail
• US V. Takeda Will Be Useful In Off-Label Promotion Cases
• FDA Wise To Duck High Court Off-Label Ruling, Attys Say
• Pay-For-Delay Antitrust Test Sets Bar Too High: FTC Official
• US Pushes Supreme Court To Reverse Design Defect Ruling
• Kirkland IP Pro Heads to Sheppard Mullin
• Pa. Devicemaker Sues Bard To Overturn USPTO Decision
• 7th Circ. Asked To Revive Walgreen, Par RICO Suit
• NuVasive Noncompete Too Restrictive, Device Seller Says
• SEC Urges 2nd Circ. To Uphold Debarment For Takeda Exec
• Sargon Enterprises V. USC: A Step Toward Daubert
• HIPAA Update Will Shake Up Marketing, Fundraising Efforts
• Novartis Faces Probe Over Trade With Iran
• Roche Accuses Accutane Judge Of 'One-Sided' Remarks
• 3rd Circ. Shuts Down Ethypharm Antitrust Suit Against Abbott
• FTC Tells Justices Pay-For-Delay 'Presumptively Unlawful'
• Dem. Wants Repeal Of $500M Amgen 'Fiscal Cliff' Gift
• Drugmaker, FDA Agree On Terms To Fix Production Issues
• Watson Boosts Women's Health Holdings In $305M Uteron Deal
• Life Sciences Group Of The Year: Weil Gotshal
• Schoeman Expands To New Digs In 5th Ave. Landmark
• Ex-McDermott Atty Fed Client IP To Family Co., Suit Says
• The Broad Reach Of New 'Failure-To-Warn-FDA' Claims
• Allergan Puts Up $958M For Migraine Treatment Maker
• DC Circ. Sides With DEA On Marijuana Classification
• GSK Says E-Discovery Co.'s CEO Is Holding Data Hostage
• Attys Agree To $143M Fee Split In $2.3B Avandia MDL
• FDA Approves Allergan's Botox For Overactive Bladders
• J&J Foresaw 40% Failure Rate In Hip Implants, Doc Shows
• Impax Denied Parkinson's Drug Approval Over Plant Issues
• Novel Infringed Braintree's Laxative Patent, Judge Rules
• Life Sciences Group Of The Year: Sidley Austin
• Dr. Reddy's Generic Found Not To Infringe Lunesta Patent
• Lone Pine's Impact On Pharma Products Litigation
• Grant & Eisenhofer Sued Over Share Of $84M Abbott Award
• Noncounty Plaintiffs Booted From Ill. J&J Suits
• Alzheimer's Drug Claims Already Failed Once, Pfizer Says
• Europe Moves To Suspend Merck Cholesterol Drug
• Life Technologies Feeds LBO Rumors
• FDA Defends Approval Of Generic Acetaminophen OD Drug
• Judge Won't Nix Apotex Suit Over Drugmaking IP
• Lawmakers Vow To Revive Pay-For-Delay Deal Ban
• FDA Clarifies Rules For Combination Medical Products
• Life Sciences Group Of The Year: Skadden
• US Calls OxyContin FCA Suit 'Parasitic'
• Stryker Offers $771M For Hong Kong Orthopedics Maker
• FDA Rule May Be Lose-Lose Scenario For Metal-Hip Makers
• FTC Pay-For-Delay Stats Show Androgel Stakes Are High
• Swiss Pharma Co. Shakes Suit Over $120M Supply Contract
• J&J, Boston Scientific Escape Off-Label Marketing Suit
• Life Sciences Group Of The Year: Fish & Richardson
• Roche's Win Over $12M Accutane Judgments Stands In NJ
• Covidien Dodges Surgical Stapling Class Claims For Now
• Cohen Milstein Survives DQ Bid In Lipitor MDL
• Actelion Says Antitrust Law Can't Make It Sell To Rivals
• Next On SCOTUS: A Significant Case For Drug Manufacturers
• OneBeacon Must Defend Vitamin Co. In Distribution Fight
• Stryker Field Service Reps Win Class Cert. In FLSA Suit
• NFL Doc Blames Smith & Nephew For $2.2M Malpractice Suit
• Life Sciences Group Of The Year: Covington & Burling
• Pfizer Says Off-Label Marketing FCA Suit Falls Short
• Hemispherx Lied About Immune Disorder Drug, Investor Says
• High Court Mulls Limits Of US Agency Powers In FCC Row
• NuAire, Merrill Agree To Drop Incubator Recall Fight
• Pfizer Settles Chantix Suit Slated For Bellwether Trial
• Smith & Nephew's $85M Patent Win Revived By Fed. Circ.
• Merck Says Fosamax Femur Fracture Claims Are Preempted
• Fighting Through The Storm: Employment Law Year In Review
• Where Calif. Stands On A New Product Liability Trend
• New Tests Set To Turn Food Litigation On Its Head
• White House Pressed Again Over Doc Payment Sunshine Rule
• Patheon Says JV Partner Can't Sue Over $255M Acquisition
• GSK's Generic Flonase Antitrust Deal Gets Green Light
• Biotronik Escapes Suit Over Defective Defibrillators
• Supplement Co. Can't Sue FDA Officer Over Product Seizure
• 6th Circ. Asked To Revive Suits Alleging Generic Reglan Harm
• Noteworthy Product Liability Decisions Of 2012: Part 2
• Skowron Fights $10.2M Morgan Stanley Payment At 2nd Circ.
• Hatch-Waxman Safe Harbor Murky After High Court Rejection
• 9th Circ. Further Muddies Case For Device Preemption
• Cigna Sued Over Denials On Heart Monitoring Device
• Chinese Bidder Draws Closer To Complete Genomics Buy
• GSK To Shell Out $21.5M To Exit Wellbutrin Antitrust Suit
• Top Court Won't Consider Mylan's Patent Battle Over Amrix
• FDA Warns St. Jude Over Production Of Heart Device
• Fla. Hospital Again Denied Cert. In $867M Drug Antitrust Suit
• Apotex Challenge To Abilify IP Won't Get High Court Hearing
• Synthes Owes $1.2M In Surgical Tool Deal, Suit Says
• Justices Invite SG's Opinion In Pfizer Asbestos Case
• Covington & Burling Opens 3rd Asia Outlet In Shanghai
• FAQs About Mass. Medical Marijuana Law
• Ala. Ruling May Mark Post-Mensing Trend For Brand Liability
• SAC Unit Will Try To Shake Insider Trading Claims
• J&J Exec Says Vaginal Mesh Product Passed Safety Tests
• 4th Circ. Backs Dismissal of Takeda Whistleblower Suit
• EU Says No New Evidence Of Clot Risks In Contraceptives
• Brand-Name Makers Can Face Generic-Drug Suits: Ala. Court
• Roche Wants 40 Accutane Suits Junked For Lack Of Experts
• FDA Yanks Rule Shielding Docs In Misconduct Inquiries
• J&J Hit With Five Suits Over Tylenol In Pa. Court
• BioMimetic Triumphs Over Investors' Fraud Class Action
• Pharmaceutical Product Switching: Antitrust Pitfalls
• Herbalife Defends Against Ackman's 'Pyramid Scheme' Attack
• J&J Failed To Warn Of Vaginal Mesh Risks, NJ Jury Told
• 9th Circ. Revives Paraplegic Man's Medtronic Pain Pump Suit
• Teva Wants Strict FDA Review For Biogen's Rival MS Drug
• New Civil Litigation Firm NastLaw Launches In Philly
• FDA Orders Cuts To Sleep-Aid Dosages Over Car Crash Risks
• The Split On FDA Requirement Of Graphic Smoking Warnings
• FDA Instructs Opioid-Drug Makers On Abuse Deterrents
• SEC Opens Herbalife Probe Following Pyramid Scheme Barb
• Ex-InterMune CEO Sues HHS Over 5-Year Program Ban
• State Suits To Protect Citizens Not Class Actions: 2nd Circ.
• Cooperator In Whitman Insider Trading Case Dodges Prison
• Fed. Circ. Mulls Discovery Rights In Patent Re-Exams
• Purdue, Ranbaxy Settle IP Fight Over Generic Oxycontin
• ViroPharma Denied Block On Generic Vancocin Approval
• McDermott Adds Greenberg Securities, Life Sciences Partner
• Rite Aid, Others Jump Into Pay-For-Delay MDL Against Pfizer
• Sequenom Pushes Fed. Circ. To Bar Ariosa Prenatal Test
• Allergan Sues To Stop Generic Eyelash-Growth Drug
• FDA Weighs St. Jude's Promise Of Durata Production Fixes
• Davis Wright Adds Ex-Goodwin Procter Patent Atty In SF
• Forest Labs Skirts Sanctions In Lexapro, Celexa Suicide MDL
• Avon Hit With False Ad Suit Over Anti-Aging Product Claims
• Noteworthy Product Liability Decisions Of 2012: Part 1
• Elan Investors Hit SAC With Insider Trading Class Action
• Cordis Case May Open Door To Discovery In Patent Re-Exams
• Judge Tosses Cooper Co. Investor Suit Over Lens Recall
• Pfizer, Investors Lose Sanctions Bids In Arthritis Drugs Case
• J&J Diabetes Drug Effective But Carries Risks, FDA Says
• SEC's Case Against Ex-Home Diagnostics CEO Reopened
• WilmerHale Welcomes Back Life Sciences Pro
• DOJ Wants Trustee In Meningitis Pharmacy Bankruptcy
• Fosamax MDL Plaintiff Slams Jury Instructions At 2nd Circ.
• McDermott Adds 2 Ex-Epstein Health Care Attys In DC
• Bayer Yaz Patents Are Obvious, Sandoz Tells Fed. Circ.
• Dykema Opens Minneapolis Office With IP, Corporate Focus
• Medtronic Wants Off-Label Marketing FCA Suit Junked
• Texas Could Lead The Nanotech Revolution
• Pros And Cons Of Proposed Medicare Smart Cards
• Fresenius Seeks To Trim FCA Suit Over Medicare Bills
• UnitedHealth Takes Reimbursement Fight To Supreme Court
• Health Spending Still Growing, But Slowly, Report Says
• Top Court's Denial Won't Be Last Word On Claim Construction
• Novartis Sues Alvogen To Block Generic Dementia Patch
• ITC Nixes Invisalign IP Enforcement Action
• FTC Often Forces Fixes In Pharma Probes, Stats Show
• Justices Weigh Class Action Fairness Act's Removal Power
• White House Pressed To Approve Doc Payment Sunshine Rule
• King Pharma Says Patent Deal Didn't Bar Skelaxin Generic
• Supreme Court Won't Review Medicare Reimbursement Denials
• NIH Stem Cell Research Funding Won't Get High Court Review
• Covington Guides Illumina In $350M Buy Of Verinata
• 'Fungi-Nail' False Ad Suit Will Stay In Federal Court
• Mass Gov. Proposes Overhaul To Compounding Oversight
• Hospira Drug Shortage Suit Must Be Revived, 11th Circ. Told
• Ind. Gets More Time To Mull $48M Healthpoint FCA Deal
• MIT Sues Shire Over Cell-Growing Mesh IP
• Pentagon Can Unilaterally Cap Tricare Drug Rates: DC Circ.
• Pfizer, Endo Pay $50M To Settle Drug Price Inflation Claims
• Whistleblower Pushes To Revive Boston Scientific FCA Suit
• Watchdog Blasts 5-Hour Energy Maker Over 'Crash' Claim
• Foley Lands 29-Year McDermott Vet For Health M&A Team
• Medtronic Stole Heart Surgery Device IP, Patent Holder Says
• Wyeth Ends Employees' ERISA Action With $2M Deal
• Gov't Loses Bid To Seal Docs In FDA Email Spying Case
• 5th Circ. Lets Chubb Off Hook In $20M Diet Aid Coverage Row
• Whistleblower Can't Fight Amgen's $612M Aranesp Deal: Judge
• Epstein Becker Welcomes Health Care Pro Back To Firm
• Life Sciences Forecast For Middle East And North Africa
• More Gatekeeper Roles And Obligations For Trial Courts
• Forest Labs, Glenmark End Blood Pressure Drug IP Fight
• Greenwich Sues To Duck Cleanup Costs At NJ Becton Site
• SAC, Founder Face Investor Suit Over Insider Trading Scandal
• Warburg Pincus Puts Up $195M For Specialty Drug Co.
• J&J Wins Rapid Approval Of Specialized TB Drug
• Hughes Hubbard Lures Ex-Shook Hardy Product Liability Vet
• Isis Accused Of Hiding Cholesterol Drug's Safety Risks
• Ranbaxy Foils Mylan's Challenge To Valsartan Exclusivity
• Recent Past Is Prologue To Life Sciences Regulation
• How Caronia Could Reshape Government Investigations
• Life Sciences Cases To Watch In 2013
• Life Sciences Regulation To Watch In 2013
• IP Cases To Watch In 2013
• Competition Regulation And Legislation To Watch In 2013
• Law360 Selects Top Practice Groups Of The Year